Literature DB >> 20408872

Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.

Ayalew Tefferi, Ralph Levitt, Terra L Lasho, Ryan A Knudson, Rhett P Ketterling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20408872     DOI： 10.1111/j.1600-0609.2010.01458.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN： 0902-4441            Impact factor:   2.997


× No keyword cloud information.
  7 in total

1.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

2.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

3.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

4.  BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just Unexplored.

Authors:  H S Darling; Rajiv Kumar; Rajan Kapoor; Jasjit Singh; Tarun Verma
Journal:  Indian J Hematol Blood Transfus       Date:  2017-12       Impact factor: 0.900

5.  Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.

Authors:  Friederike Pastore; Stephanie Schneider; Oliver Christ; Wolfgang Hiddemann; Karsten Spiekermann
Journal:  Exp Hematol Oncol       Date:  2013-09-05

Review 6.  Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

Authors:  Gilbert Bader; Bernard Dreiling
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

7.  Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera.

Authors:  Mariana Lorenzo; Sofia Grille; Mariana Stevenazzi
Journal:  J Hematol       Date:  2020-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.